בליאומיצין Bleomycin PFI - PFI

בליאומיצין Bleomycin PFI - PFI
התוויות	Bleomycin is useful in the management of the following neoplasms: Squamous cell carcinoma affecting the mouth, nasopharynx and paranasal sinuses, larynx, oesaphagus, cervix, vagina, penis and skin. Well differentiated tumors usually respond better than anaplastic ones. Hodgkin's disease and other malignant lymphomas, including mycosis fungoides. Testicular carcinoma (seminoma and no seminoma) . Malignant effusions of serous cavities (intrapleural and intraperitoneal). Secondary indications in which bleomycin has been shown to be of some value include metastatic malignant melanoma, carcinoma of the thyroid lung and bladder. Local treatment of refractory warts. Bleomycin can be used as a single agent, but is generally used in combination with other cytotoxics and/or with radiation therapy

מידע ברשת

בליאומיצין Bleomycin PFI - PFI


מרכיב פעיל	BLEOMYCIN SULFATE
קבוצה פרמקולוגית (ATC)	"OTHER CYTOTOXIC ANTIBIOTICS"
שם התרופה	"בליאומיצין PFI®" (קישור לדף התרופה במאגר משרד הבריאות)
סל הבריאות	כלול
מסגרת הכללה בסל	תרופה מוגבלת לשימוש בבתי חולים או אשפוז יום.
התוויות	Bleomycin is useful in the management of the following neoplasms: Squamous cell carcinoma affecting the mouth, nasopharynx and paranasal sinuses, larynx, oesaphagus, cervix, vagina, penis and skin. Well differentiated tumors usually respond better than anaplastic ones. Hodgkin's disease and other malignant lymphomas, including mycosis fungoides. Testicular carcinoma (seminoma and no seminoma) . Malignant effusions of serous cavities (intrapleural and intraperitoneal). Secondary indications in which bleomycin has been shown to be of some value include metastatic malignant melanoma, carcinoma of the thyroid lung and bladder. Local treatment of refractory warts. Bleomycin can be used as a single agent, but is generally used in combination with other cytotoxics and/or with radiation therapy
שם יצרן	BAXTER ONCOLOGY GmbH, GERMANY
שם בעל הרישום	MEGAPHARM LTD